Prelude Therapeutics Inc
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and oral… Read more
Prelude Therapeutics Inc (PRLD) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.327x
Based on the latest financial reports, Prelude Therapeutics Inc (PRLD) has a cash flow conversion efficiency ratio of -0.327x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.11 Million) by net assets ($58.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Prelude Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Prelude Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Prelude Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Prelude Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Takkt AG
XETRA:TTK
|
0.023x |
|
Viatron Technologies Inc
KQ:141000
|
-0.048x |
|
Oriental Hotels Limited
NSE:ORIENTHOT
|
0.059x |
|
Dream International Limited
PINK:DRMMF
|
0.088x |
|
Blackrock Silver Corp
OTCQX:BKRRF
|
-0.284x |
|
Sarana Meditama Metropolitan
JK:SAME
|
0.031x |
|
Taipei Star Bank
TWO:5863
|
-0.366x |
|
Thaivivat Holdings Public Company Limited
BK:TVH
|
N/A |
Annual Cash Flow Conversion Efficiency for Prelude Therapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Prelude Therapeutics Inc from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $131.46 Million | $-102.89 Million | -0.783x | -73.32% |
| 2023-12-31 | $237.09 Million | $-107.06 Million | -0.452x | -5.40% |
| 2022-12-31 | $195.44 Million | $-83.73 Million | -0.428x | -46.63% |
| 2021-12-31 | $285.90 Million | $-83.53 Million | -0.292x | -34.25% |
| 2020-12-31 | $212.18 Million | $-46.18 Million | -0.218x | -141.90% |
| 2019-12-31 | $-49.41 Million | $-25.66 Million | 0.519x | -9.01% |
| 2018-12-31 | $-22.69 Million | $-12.95 Million | 0.571x | -- |